DAWN

NEUTRALM&A

Day One Biopharmaceuticals, Inc

2026-04-21

Price

$21.49

+0.05%

Score12.2Priority

Signals7/8 DNA1/13 Act · 1/4 Risk

SentimentNEUTRALScore: 5

Volume1.3xvs 20d avg

Analysis

Day One Biopharmaceuticals (DAWN) is trading at $21.49, effectively pinned just one cent below its $21.50 all-cash acquisition price by Servier Pharmaceuticals. The technical signals (SURGE, ALPHA_MALE) and exceptionally low 1.4% realized volatility are classic artifacts of merger arbitrage rather than organic price discovery. Recent SEC filings confirm the tender offer is progressing smoothly, with early FTC HSR clearance already secured and major stakeholders tendering their shares. The broader RISK_ON macro regime and extremely tight credit spreads (0.81%) provide absolute market conviction that deal financing is secure and the acquisition will close without friction.

Fired Signals

SURGEALPHA MALEQUIET STORMSTEADY CLIMBGOLDEN CROSSBOLLINGER SQUEEZEPERFECT STACKSELLER FATIGUEWEAK FINISH

Key Takeaways

M&A Arbitrage Play: DAWN is acting as a pure proxy for its $21.50 cash buyout from Servier, capping any further upside and rendering the stock a fixed-income equivalent [1.4].
Regulatory De-risking: Early FTC HSR clearance and major shareholder tenders (e.g., Access Industries tendering 12.9M shares) indicate an imminent and smooth deal closure.
Signal Context: Strong technical momentum signals and extremely low volatility are entirely driven by the M&A price peg, meaning standard directional trading strategies do not apply.

← Back to 2026-04-21 View Full DAWN History →Yahoo Finance &nearr;